Insider Buying: Zoetis (NYSE:ZTS) Director Purchases $151,760.00 in Stock

Zoetis Inc. (NYSE:ZTS) Director Paul Bisaro acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Zoetis Stock Down 1.8%

NYSE:ZTS opened at $74.11 on Friday. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23. The company has a 50-day moving average of $112.28 and a 200 day moving average of $120.94. The firm has a market cap of $31.07 billion, a PE ratio of 12.29, a price-to-earnings-growth ratio of 1.23 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several analyst reports. Bank of America increased their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, UBS Group decreased their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $137.50.

Hedge Funds Weigh In On Zoetis

Several hedge funds and other institutional investors have recently modified their holdings of the stock. RFG Advisory LLC raised its position in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares during the last quarter. YANKCOM Partnership raised its position in shares of Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after purchasing an additional 81 shares during the last quarter. Evergreen Capital Management LLC raised its position in shares of Zoetis by 3.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after purchasing an additional 85 shares during the last quarter. Beese Fulmer Investment Management Inc. raised its position in shares of Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares during the last quarter. Finally, Quest 10 Wealth Builders Inc. raised its position in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.